{"entity":{"id":"nct05899049","kind":"trial","name":"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study","aka":[],"tldr":"A phase 3 trial of Pembrolizumab, Belzutifan and Lenvatinib in renal cell carcinoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","summary":"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study is a phase 3 interventional study registered as NCT05899049 by Merck Sharp & Dohme LLC, with 251 participants enrolled, started 2022-07-27 and due to reach its primary completion in 2026-02-04. Interventions recorded: Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab and Lenvatinib.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05899049","url":"https://clinicaltrials.gov/study/NCT05899049"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","belzutifan","lenvatinib"],"companies":["merck","eisai"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05899049","phase":"3","setting":"An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, as First-Line Treatment in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)","sponsor":"Merck Sharp & Dohme LLC","enrolled":251,"outcomes":[]},"route":"/trials/nct05899049/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"belzutifan","kind":"drug","name":"Belzutifan","route":"/drugs/belzutifan/"},{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"eisai","kind":"company","name":"Eisai","route":"/companies/eisai/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}